ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Public Health Service: NIEHS, CDC to Study Population Exposure to Environmental Estrogens

December 12, 1997

Centers May Become More specialized, Klausner Tells AACI

April 26, 1996

Congress Hasn’t Completed Action Yet On Major Health Bills; Reauthorization Fight In 1988-89

July 17, 1987

In Brief: Twenty-Nine Percent Of Approved Organ Systems Applications Funded In February, May Cycles

November 4, 1983

Research Advocates Prepare to Face Republican-led Congress

December 19, 2014

In Brief: Deadline June 1 For Cancer Research Institute Grants; Chabner To Present Karnofsky Lecture

May 3, 1985